Arrowhead Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Arrowhead Pharmaceuticals 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About ARWR

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. 

CEO
Christopher Richard Anzalone
CEOChristopher Richard Anzalone
Employees
711
Employees711
Headquarters
Pasadena, California
HeadquartersPasadena, California
Founded
1989
Founded1989
Employees
711
Employees711

ARWR Key Statistics

Market cap
10.55B
Market cap10.55B
Price-Earnings ratio
-34.89
Price-Earnings ratio-34.89
Dividend yield
Dividend yield
Average volume
1.77M
Average volume1.77M
High today
$76.51
High today$76.51
Low today
$74.53
Low today$74.53
Open price
$75.43
Open price$75.43
Volume
1.14M
Volume1.14M
52 Week high
$82.26
52 Week high$82.26
52 Week low
$14.30
52 Week low$14.30

Stock Snapshot

As of today, Arrowhead Pharmaceuticals(ARWR) shares are valued at $74.95. The company's market cap stands at 10.55B, with a P/E ratio of -34.89.

On 2026-05-25, Arrowhead Pharmaceuticals(ARWR) stock traded between a low of $74.53 and a high of $76.51. Shares are currently priced at $74.95, which is +0.6% above the low and -2.0% below the high.

The Arrowhead Pharmaceuticals(ARWR)'s current trading volume is 1.14M, compared to an average daily volume of 1.77M.

During the past year, Arrowhead Pharmaceuticals(ARWR) stock moved between $14.30 at its lowest and $82.26 at its peak.

During the past year, Arrowhead Pharmaceuticals(ARWR) stock moved between $14.30 at its lowest and $82.26 at its peak.

ARWR News

Simply Wall St 9h
How REDEMPLO Launch Momentum And SHASTA Phase 3 Milestones At Arrowhead Pharmaceuticals Has Changed Its Investment Story - simplywall.st

...

How REDEMPLO Launch Momentum And SHASTA Phase 3 Milestones At Arrowhead Pharmaceuticals Has Changed Its Investment Story - simplywall.st
TipRanks 5d
Arrowhead’s ARO-CFB Kidney Trial Completion: What Investors Should Watch Next

Arrowhead Pharmaceuticals, Inc. (ARWR) announced an update on their ongoing clinical study. Start a conversation with TipRanks’ trusted, data-backed investment...

Analyst ratings

85%

of 13 ratings
Buy
84.6%
Hold
15.4%
Sell
0%

People also own

Based on the portfolios of people who own ARWR. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.